跳至主要内容
临床试验/NCT04627974
NCT04627974进行中(未招募)不适用

A Prospective Study to Evaluate the Long-term Effectiveness, Safety, and Performance of the Saluda Medical's EvokeTM Closed-Loop Spinal Cord Stimulation System to Treat Patients With Chronic Pain of the Trunk and/or Limbs

Saluda Medical Pty Ltd16 个研究点 分布在 4 个国家目标入组 70 人开始时间: 2020年8月5日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
70
试验地点
16
主要终点
Percent Change in Visual Analogue Scale (VAS) Pain

研究概览

简要总结

The objective of this multicountry, multicentre, prospective study is to evaluate the long-term clinical effectiveness, safety, and performance of the Evoke System in the treatment of chronic pain of the trunk and/or limbs in a real-world population.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Eligible for therapy according to the Evoke System indications for use statement and labelling requirements
  • Willing and capable of giving informed consent and able to comply with study-related requirements, procedures, and visits
  • Baseline VAS pain rating ≥60 mm in the primary area of pain

排除标准

  • No further exclusion criteria

研究组 & 干预措施

ECAP-controlled, closed-loop SCS

Spinal cord stimulation that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude

干预措施: Evoke Spinal Cord Stimulation (SCS) System (Device)

结局指标

主要结局

Percent Change in Visual Analogue Scale (VAS) Pain

时间窗: 3-months post-implant

Visual Analogue Scale (VAS) to rate pain intensity (0mm \[no pain\] to 100mm \[worst pain imaginable\])

次要结局

  • Incidence of device- and procedure-related adverse events(through 60-months post-implant)
  • Measurement of ECAPs by the Evoke SCS System(through 60-months post-implant)

研究者

发起方
Saluda Medical Pty Ltd
申办方类型
Industry
责任方
Sponsor

研究点 (16)

Loading locations...

相似试验